

## Product Data Sheet

Product Name: Fesoterodine Fumarate

Cat. No.: GC16087

### Chemical Properties

Cas. No. 286930-03-8

Chemical Name (E)-but-2-enedioic acid;[2-[(1R)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-methylpropanoate

SMILES CC(C)C(=O)OC1=C(C=C(C=C1)CO)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2.C(=CC(=O)O)C(=O)O

Formula  $C_{30}H_{41}NO_7$  M.Wt 527.65

Solubility  $H_2O$  : 100 mg/mL (189.52 mM; Need ultrasonic); DMSO : 100 mg/mL (189.52 mM; Need ultrasonic) Storage Store at  $-20^{\circ}C$

General tips For obtaining a higher solubility , please warm the tube at  $37^{\circ}C$  and shake it in the ultrasonic bath for a while. Stock solution can be stored below  $-20^{\circ}C$  for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

### Background

Fesoterodine Fumarate is an antimuscarinic agent and is rapidly de-esterified to its active metabolite 5-hydroxymethyl tolterodine that is a muscarinic receptor antagonist. IC50 value: Target: mAChR. Fesoterodine has the advantage of allowing more flexible dosage than other muscarinic antagonists. Its tolerability and side effects are similar to other muscarinic antagonists and as a new drug seems unlikely to make great changes in practices of treatment for overactive bladder.

### References:

- [1]. Staskin David; Khullar Vik; Michel Martin C et al. Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder. *Neurourology and urodynamics* (2011), 30(8), 1480-5.
- [2]. Vella Maria; Cardozo Linda Review of fesoterodine. *Expert opinion on drug safety* (2011), 10(5), 805-8.
- [3]. Malhotra Bimal; Alvey Christine; Gong Jason et al. Effects of fesoterodine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. *British journal of clinical pharmacology* (2011), 72(2), 257-62.
- [4]. Michel MC. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. *Expert Opin Pharmacother.* 2008 Jul;9(10):1787-96.
- [5]. Fesoterodine

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA